Seagen
Bothell, Washington, United States
Seagen, founded in 1998, is a biotechnology company dedicated to developing and commercialising transformative cancer therapies. By leveraging its proprietary antibody-drug conjugate (ADC) technology, Seagen offers innovative treatments that have the potential to significantly improve outcomes for cancer patients. With its headquarters in Bothell, Washington, the company is committed to pioneering new approaches in oncology, challenging the limitations of conventional treatments.
The organisation prioritises research and development, focusing on producing targeted therapies that deliver potent anti-cancer activity directly to tumour cells. Its ADC technology is at the forefront of this effort, combining monoclonal antibodies with potent cell-killing agents. Seagen's commitment to innovation is evident in its robust clinical pipeline and strategic partnerships aimed at expanding its therapeutic reach.
Seagen continues to grow its global presence, with a strong emphasis on collaboration and partnerships to enhance its product offerings. The company is actively engaged in advancing healthcare solutions that address unmet medical needs in oncology. By prioritising patient-centric approaches and maintaining a focus on scientific excellence, Seagen remains a leader in the quest to transform cancer treatment paradigms worldwide.
- HQ Location
- Bothell, Washington, USA
- Employee Count
- 1500
- CEO
- David Epstein
- Revenue
- $1.176 bn
We're preparing new articles for you
Our dedicated editorial team is currently in the process of curating the most relevant and insightful Seagen content to bring you the best stories. We appreciate your patience and invite you to check back for updates.
